System Transmission

Top Signal

100#1 JOB

Activity

2188Ripe

+959 today

System

Livenow

Terminal Asset View

stockNASDAQ

PROK

$2.25+0.45%

ProKidney Corp - Class A

Ripe

Official Site

Market value

24H Total Traded

Total supply

52-Week Range

Ripeness Index

80Ripe

Live Analysis Active

Company Mission

ProKidney develops cell therapy treatments for people with chronic kidney disease. Their main product is a treatment that uses a patient's own cells to help repair damaged kidneys. The company makes money by conducting clinical trials and hopes to eventually sell approved treatments to hospitals and healthcare providers.

PRO

Industry Context

The biotech industry focuses on developing new medical treatments using biological systems. Companies in this space often spend years in research and clinical trials before potentially earning revenue from approved treatments. Cell therapy is a growing area within biotech that uses living cells to treat diseases.

Scoring Terminal

Intelligence Pipeline Active

Algorithm Verified

Asset Diagnostics

ProtocolV2.1_TACTICAL

Technical Matrix

Scanning

85Matrix

Market Momentum

50.7— Holding Steady

Trend Strength

50— Active Setup

Momentum Engine

Ready

Velocity Score

StaticOptimal FlowMax Vel

Trading Activity

1.1x— Normal Volume

Today's Change

0.45%— Live Performance

Social Frequency

Listening

Social Freq

0.0x

Normal Vol

X/Twitter Activity

0.0x— Streaming

Reddit Buzz

0.0x— Synced

System Observation

ANALYSIS:Price energy is building quickly for a potential move. Bullish alignment confirmed.

Lat14ms

BufOK

Positive Catalysts

No active score modifiers detected

Risk Flags

52W Threshold-1

Price is extended significantly above 52-week highs.

Banana Farmer tracks 100's of signals to synthesize this proprietary score.

0Velocity

Awaiting Data

Social Intelligence Pulse.

Our engine is currently indexing PROK across global social channels to detect early sentiment shifts and technical alignment.

XMonitoring

RedditMonitoring

WebMonitoring

Social GrowthPending

Signal CoverageInitializing

Signal Catalysts

Intelligence Narrative Connected

Updated 05:01 PM UTC

As-of 03-15-2026 16:45 UTC

Develops cell therapies to treat kidney disease and makes money by selling these treatments to hospitals and clinics.

Weekly price swings are getting smaller, suggesting the stock is coiling tighter before a potential larger move.

Biotech sector showing renewed interest in cell therapies, which could benefit companies with late-stage clinical programs.

Educational only. Not investment advice.

Precision Intelligence Model

Live Terminal Stream

Loading chart...